

16 March 2022

Subject: Treatment of renal cell carcinoma and melanoma

I have a freedom of information request regarding the treatment of renal cell carcinoma and melanoma. Could you please answer the following questions:

Please find Information as available from RISOH (regional information system for Oncology & Haematology)

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- Avelumab + Axitinib **12**
- Axinitib
- Cabozantinib **16**
- Everolimus
- Lenvantinib + Everolimus
- Nivolumab **30**
- Nivolumab + Ipilimumab **8**
- Pazopanib
- Pembrolizumab + Axitinib
- Pembrolizumab monotherapy
- Sunitinib **12**
- Temsirolimus
- Tivozanib **15**
- Other active systemic anti-cancer therapy

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib
- Dabrafenib **3**
- Dabrafenib AND Trametinib **18**
- Encorafenib AND Binimetinib **26**
- Ipilimumab
- Ipilimumab AND Nivolumab **11**
- Nivolumab **10**
- Pembrolizumab **49**
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy
- **Tebentafusp MAP <5 Lenvatinib & Pembro <5**
- Palliative care only

16 March 2022

Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

This information is not available on RISOH

- Cobimetinib
- Dabrafenib
- Dabrafenib AND Trametinib
- Encorafenib AND Binimetinib
- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

For the period October – December 21 is 35 patients